Uncategorized

Lilly and Engage Bio tie the knot with $202M acquisition

Published

on

Eli Lilly joins hands with Engage Bio, acquiring the DNA delivery platform developer in hopes of bolstering its genetic medicines portfolio.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version